That essential morning coffee may be a placebo
For many people, the day doesn’t start until their coffee mug is empty. Coffee is often thought to make you feel more alert, so people drink it to… read more.
For many people, the day doesn’t start until their coffee mug is empty. Coffee is often thought to make you feel more alert, so people drink it to… read more.
The key challenges in heart failure treatment include reaching the target dose, awareness of drug-specific issues that influence effectiveness and tackling adherence problems, according to Paul Forsyth, Lead… read more.
Pivotal data from the Phase III XTEND-Kids study evaluating efanesoctocog alfa [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein] once-weekly prophylaxis in previously treated patients younger than 12 years of… read more.
An international team of researchers has developed a new method to deliver drugs into the inner ear. The discovery was possible by harnessing the natural flow of fluids… read more.
Current thinking advocates the use of ‘four pillars of heart failure therapy’. Paul Forsyth, Lead Pharmacist, Clinical Cardiology at NHS Greater Glasgow and Clyde, explains how this treatment… read more.
UCB announced Rystiggo (rozanolixizumab-noli) has been approved by the FDA for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or anti-muscle-specific… read more.
Osteoarthritis was long considered to be the result of wear and tear in advanced age. In the meantime, more and more studies are linking the degradation of articular… read more.
A recent publication described the holistic approach to drug therapy in a patient with heart failure – an area where treatment has changed considerably over the past 30… read more.
AstraZeneca’s Xigduo XR (dapagliflozin and metformin hydrochloride extended-release), a once-daily fixed-dose combination, has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adults with… read more.
The FDA recently approved the Janus kinase (JAK) inhibitor ritlecitinib (Litfulo) for adults and adolescents with severe alopecia areata. It is, so far, the only treatment approved by the FDA… read more.
A new study by Uppsala University shows that a higher body mass index (BMI) increases the risk of five different rheumatic diseases: rheumatism, osteoarthritis, gout, psoriatic arthritis and… read more.
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Mircera… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.